clinical trial · NCT05422222
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
Vertex Pharmaceuticals Incorporated·phase3·recruiting·n = 210
Cystic FibrosisVX-121/TEZ/D-IVA
brief summary
The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
started
Jun 21, 2022
primary completion
Jun 30, 2030
completion
Jun 30, 2030
last updated
Mar 30, 2026
official title
A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol